Business
Statement re. Silicon Valley Bank
Statement re. Silicon Valley Bank.
About this update from Renalytix Plc
[{"type":"text","content":"\n \n \n Renalytix plc \n \n \n (\"Renalytix\" or the \"Company\")\n \n \n \n \n \n Statement re. Silicon Valley Bank\n \n \n \n \n \n \n \n \n LONDON and SALT LAKE CITY, March 13, 2023\n \n -- \n \n \n Renalytix plc\n \n \n \n (NASDAQ: RNLX) (LSE: RENX) is aware of media reports indicating the closure of Silicon Valley Bank (\"SVB\"). The Company does not hold any cash at SVB and it does not have a banking relationship with SVB.\n \n \n \n \n \n For further information, please contact:\n \n \n \n \n \n \n \n \n \n \n Renalytix plc \n \n \n \n \n \n \n www.renalytix.com\n \n \n \n \n \n \n \n \n James McCullough, CEO \n \n \n \n \n \n Via Walbrook PR \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Stifel (Nominated Adviser, Joint Broker)\n \n \n \n \n \n Tel: 020 7710 7600\n \n \n \n \n \n \n \n Alex Price / Nicholas Moore \n / Nick Harland / Samira Essebiyea\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Walbrook PR Limited\n \n \n \n \n \n Tel: 020 7933 8780 \n or \n \n [email protected]\n \n \n \n \n \n \n \n \n Paul McManus / Lianne Applegarth\n \n \n \n \n Mob: 07980 541 893 / 07584 391 303\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n About Kidney Disease\n \n \n \n Kidney disease is a public health epidemic affecting over 850 million people globally.1 The Centers for Disease Control and Prevention estimates that 15% of U.S. adults, or approximately 37 million people2, have chronic kidney disease (CKD). Nearly 95% of people with CKD are in early stages 1-33. Despite its magnitude, early-stage (1-3) CKD is underdiagnosed and undertreated, largely because it's asymptomatic at this time in the disease. As many as 9 in 10 adults with CKD, and about 2 in 5 adults with severe CKD do not know they have the condition.3\n \n \n \n \n \n \n About Renalytix\n \n \n \n Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enab...